Patient discomfort · Children (80% aged <= 16 years) with a Class II division 2 malocclusion (deep bite and retroclined upper front teeth)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Development and eruption of the second permanent molar · Children aged 5 to 15 years with a compromised first permanent molar
Root closure and eruption of the second permanent molar appeared accelerated on the extraction side in a single case-control study; ungraded and not statistically tested.
1 finding from 1 review
Incidence of incisal trauma · Adolescents (age 12 to 16 years) receiving orthodontic treatment to correct prominent upper front teeth (Class II malocclusion)
The review found no eligible studies for this question.
1 finding from 1 review
Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
Final overjet · Adolescents (age 12 to 16 years) receiving orthodontic treatment to correct prominent upper front teeth (Class II malocclusion)
Removable functional appliance may leads to higher final overjet compared with fixed functional appliance (low certainty).
1 finding from 1 review
Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
Behaviour · Children and adolescents (0 to 16 years) needing dental treatment
1 finding from 1 review
Any behavioural score - Midazolam (any mode of delivery): 394 (10 studies); VERY LOW. Insufficient evidence to determine whether any specific dose of intranasal midazolam is effective; weak evidence oral midazolam…
10 studies · 394 participants
Very low
Quality of life · Children (80% aged <= 16 years) with a Class II division 2 malocclusion (deep bite and retroclined upper front teeth)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Development and eruption of the third molar · Children aged 5 to 15 years with a compromised first permanent molar
Development and eruption of the third molar appeared accelerated after early first permanent molar extraction in two studies (e.g., eruption OR 2.86, 95% CI 1.37 to 5.96); ungraded.
1 finding from 1 review
OR 2.86 [1.37, 5.96]
2 studies
GRADE not reported
Cases of typhoid fever, Year 1 · adults and children aged 5 years of age and older
Ty21a vaccine (three doses) probably leads to lower cases of typhoid fever, Year 1 compared with control (moderate certainty).
2 findings from 1 review
Fever · adults and children of 2 years of age and older
Vi polysaccharide vaccine (1 dose) showed no clear difference in fever compared with control (moderate certainty).
1 finding from 1 review
Erythema · adults and children of 2 years of age and older
Vi polysaccharide vaccine (1 dose) showed no clear difference in erythema compared with control (low certainty).
1 finding from 1 review
Incidence of typhoid fever – year 1 · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to lower incidence of typhoid fever – year 1 compared with control (moderate certainty).
1 finding from 1 review
Incidence of typhoid fever – year 2 · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to lower incidence of typhoid fever – year 2 compared with control (moderate certainty).
1 finding from 1 review
Serious adverse events · adults and children of 2 years of age and older
1 finding from 1 review
Fever · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to higher fever after Vi‐rEPA (dose1) compared with control (moderate certainty).
1 finding from 1 review
Fever after Vi‐rEPA (dose2) · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to higher fever after Vi‐rEPA (dose2) compared with control (moderate certainty).
1 finding from 1 review
Erythema · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) showed no clear difference in erythema after Vi‐rEPA (dose 2) compared with control (low certainty).
1 finding from 1 review
Swelling at injection site after Vi‐rEPA (dose 2) · adults and children of 2 years of age and older
Vi‐rEPA vaccine (2 doses) probably leads to higher swelling at injection site after Vi‐rEPA (dose 2) compared with control (moderate certainty).
1 finding from 1 review